Literature DB >> 16234291

Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency.

Peggy W G du Buf-Vereijken1, Jack F M Wetzels.   

Abstract

BACKGROUND: In patients with idiopathic membranous nephropathy, an increased urinary excretion of high (IgG) and low [beta(2)-microglobulin (beta(2)M), alpha(1)-microglobulin (alpha(1)M)] molecular weight proteins predicts prognosis and precedes renal insufficiency. We have studied the changes in the urinary excretion of these proteins in patients with idiopathic membranous nephropathy and renal insufficiency during and after treatment with cyclophosphamide and steroids, and investigated their value in predicting long-term outcome.
METHODS: Standardized measurements of urinary IgG, albumin, beta(2)M and alpha(1)M were performed at 0, 2, 6 and 12 months in 11 patients, at 12 months in 25 patients and in 17 of these last patients after 2-5 years.
RESULTS: We observed a rapid improvement of glomerular permselectivity and tubular protein reabsorption within 2 months after the start of therapy. Despite a partial remission of proteinuria within 12 months in most patients, evidence of tubulo-interstitial injury remained apparent. Neither absolute levels of urinary IgG, beta(2)M or alpha(1)M at baseline or at 12 months nor the percentage reduction between baseline and 12 months clearly predicted the occurrence of a remission or a relapse to nephrotic range proteinuria. In the case of a persistent stable remission, we observed a gradual decrease of urinary beta(2)M towards normal values.
CONCLUSIONS: In patients with idiopathic membranous nephropathy and renal insufficiency, treatment with cyclophosphamide and steroids resulted in an improvement of glomerular permeability and tubular proteinuria. Tubular proteinuria remained present for many years, even in patients with stable remission of proteinuria. Measurements of urinary proteins at 12 months after treatment start lacked predictive accuracy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234291     DOI: 10.1093/ndt/gfi219

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  American Society of Nephrology Quiz and Questionnaire 2012: glomerulonephritis.

Authors:  Fernando C Fervenza; Richard J Glassock; Anthony J Bleyer
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

Review 2.  Management of Membranous Nephropathy in Western Countries.

Authors:  Talal Alfaadhel; Daniel Cattran
Journal:  Kidney Dis (Basel)       Date:  2015-09-09

Review 3.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

4.  Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Authors:  Maria V Irazabal; Alfonso Eirin; John Lieske; Laurence H Beck; Sanjeev Sethi; Timothy M Borland; John J Dillon; Patrick H Nachman; Samih H Nasr; Lynn D Cornell; Nelson Leung; Daniel C Cattran; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2012-09-17       Impact factor: 5.992

5.  Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.

Authors:  Anneke P Bech; Julia M Hofstra; Paul E Brenchley; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-17       Impact factor: 8.237

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.